US: +1 617 696-7335 | EU: +31 317 728 104|info@ionoptix.com

Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo (2025)

2026-05-15T18:00:08-05:00

Shuvaev VV, Tam YK, Lee BW, Myerson JW, Herbst A, Kiseleva RY, Glassman PM, Parhiz H, Alameh MG, Pardi N, Muramatsu H, Shuvaeva TI, Arguiri E, Marcos-Contreras OA, Hood ED, Brysgel TV, Nong J, Papp TE, Eaton DM, Riley R, Palanki R, Musunuru K, Brenner JS, Mitchell MJ, Ferrari VA, Mui BL, Semple SC, Weppler SA, Atluri P, Margulies KB, Weissman D, Muzykantov VR. Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo. Proc Natl Acad Sci U S A. 2025 Jul 22;122(29):e2409266122. doi: 10.1073/pnas.2409266122.

A new approach to characterize cardiac sodium storage by combining fluorescence photometry and magnetic resonance imaging in small animal research (2024)

2026-05-15T18:57:27-05:00

Christa M, Dithmar F, Weinaus T, Kohlhaas M, Arias-Loza AP, Hofmann M, Elabyad IA, Gutjahr FT, Maack C, Bauer WR. A new approach to characterize cardiac sodium storage by combining fluorescence photometry and magnetic resonance imaging in small animal research. Sci Rep. 2024 Jan 29;14(1):2426. doi: 10.1038/s41598-024-52377-w.

Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3c.2373InsG in the Netherlands (2023)

2026-05-15T18:58:16-05:00

Hilderink S, Schuldt M, Goebel M, Jansen VJ, Manders E, Moorman S, Dorsch LM, van Steenbeek FG, van der Velden J, Kuster DWD. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3c.2373InsG in the Netherlands. J Mol Cell Cardiol. 2023 Dec;185:65-76. doi: 10.1016/j.yjmcc.2023.10.008.

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure (2025)

2026-05-15T18:01:07-05:00

Mohran S, Kooiker KB, Naim A, Pilagov M, Asencio A, Turner KL, Ma W, Flint G, Jiang S, Zhao J, McMillen TS, Mandrycky C, Mahoney-Schaefer M, Irving TC, Tanner BCW, Kad NM, Regnier M, Moussavi-Harami F (2025). Myosin Modulator Aficamten Inhibits Force by Altering Myosin's Biochemical Activity Without Changing Thick Filament Structure. JACC Basic Transl Sci. 2026 Jan;11(1):101449. doi: 10.1016/j.jacbts.2025.101449.

Go to Top